Discover 1 curated intelligence briefings related to this specific topic.
Industrial scale-up of Antibody-Drug Conjugates (ADCs) now demands a transition from random conjugation to site-specific bioorthogonal ligation. By integrating high-yield protein secretion platforms and multifunctional payloads like STING antagonists, manufacturers can stabilize the drug-to-antibody ratio (DAR) for complex bispecific architectures.
